JDP Therapeutics has been selected to present at the 7th Annual Biotech Showcase™ Conference at 4:30 pm Pacific Time on Monday, January 12, 2015.

BLUE BELL, PA, USA, January 7, 2015 /EINPresswire.com/ -- JDP Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco
(Presentation on January 12, 2015, at 4:30

JDP Therapeutics Inc., a privately held specialty pharmaceutical company, announced today that the company has been selected to present at the 7th Annual Biotech Showcase™ Conference at 4:30 pm Pacific Time (7:30 PM Eastern Time) on Monday, January 12, 2015. The presentation will take place in the Hearst Room at the Parc 55 Wyndham Hotel in San Francisco.

Jie Du, Ph.D., President and CEO of JDP Therapeutics, will provide an overview of the company and its activities, including the recently completed phase 3 human clinical trial (ETTAU-02) with JDP-205, the company's lead candidate, for the treatment of acute urticaria associated with acute allergic reactions.


About JDP-205
JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years. JDP-205 is projected to have a significant commercial opportunity with its peak annual sales in the range of ~$300MM.


About JDP Therapeutics Inc.
JDP Therapeutics Inc. is a privately held, clinical phase 3 stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.



For further information, please email info@jdptherapeutics.com




# # #





Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP’s ability to fund such efforts with or without partners, and other risks.

Jonathan Black
JDP Therapeutics Inc
2156618557
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.